Short Interest in Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Drops By 70.4%

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) saw a large decline in short interest in the month of June. As of June 15th, there was short interest totaling 20,390 shares, a decline of 70.4% from the May 31st total of 68,896 shares. Based on an average daily volume of 76,356 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.3% of the company’s stock are short sold.

Matinas Biopharma Trading Up 3.4%

NYSEAMERICAN:MTNB traded up $0.02 on Monday, hitting $0.66. 58,413 shares of the company’s stock traded hands, compared to its average volume of 69,312. The firm has a 50-day moving average price of $0.67 and a 200-day moving average price of $0.64. Matinas Biopharma has a 1 year low of $0.48 and a 1 year high of $3.09. The company has a market cap of $4.26 million, a PE ratio of -0.33 and a beta of 1.67.

Matinas Biopharma (NYSEAMERICAN:MTNB) last issued its earnings results on Friday, May 8th. The company reported ($0.30) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Matinas Biopharma

An institutional investor recently bought a new stake in Matinas Biopharma stock. DRW Securities LLC purchased a new stake in Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned 0.72% of Matinas Biopharma at the end of the most recent reporting period. Hedge funds and other institutional investors own 11.77% of the company’s stock.

About Matinas Biopharma

Matinas Biopharma Inc is a clinical?stage biopharmaceutical company that specializes in the development of novel lipid?based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water?soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life?threatening fungal infections.